Promising aHUS drug trial stalls after only 6 patients enrolled

NCT ID NCT03205995

Terminated Disease control Sponsor: Omeros Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the study was terminated early and only enrolled 6 people, so we have very little information about how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: narsoplimab (a monoclonal antibody given by IV and daily injections)
What this could lead to: If successful, narsoplimab could offer a new treatment option for people with aHUS, potentially improving platelet counts and controlling the disease.
What could go wrong: The trial was terminated early with only 6 participants, so results are very limited. It is unclear if narsoplimab is safe or effective, and aHUS is a rare, serious condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical hemolytic-uremic syndrome thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL HEMOLYTIC UREMIC SYNDROME THROMBOTIC MICROANGIOPATHIES

Contacts and locations

Locations

Omeros Investigational Site

Chicago, Illinois, 60643, United States
Omeros Investigational Site

Vilnius, Lithuania
Omeros Investigational Site

Lodz, Poland
Omeros Investigational Site

New Taipei City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.